Compound CVT-E002 attenuates allergen-induced airway inflammation and airway hyperresponsiveness, in vivo.
Immune modulation has been a sought after means of therapy for atopic diseases. CVT-E002 is an extract derived from North American Ginseng shown to promote T-helper-1-like responses. We determined what effect CVT-E002 could have in a mouse model of atopic asthma. We report that oral CVT-E002 inhibited the development of allergic airway inflammation and airway hyperresponsiveness. This correlated with an increased presence of interferon-γ in the lung, and also increased regulatory T cells and IL-10. The ability of CVT-E002 to induce regulatory T-cell development was also seen in human in vitro co-cultures.
Pulmonary Research Group, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Cory
C
Ebeling
Yingqi
Y
Wu
Christopher
C
Skappak
John R
JR
Gordon
Ramses
R
Ilarraza
Darryl J
DJ
Adamko
D000485:Allergens / Q000276:immunology*; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018920:Coculture Techniques; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D005894:Panax / Q000737:chemistry; D010936:Plant Extracts / Q000494:pharmacology*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
D000485:Allergens; C511203:COLD-fX; D010936:Plant Extracts; D016753:Interleukin-10; D007371:Interferon-gamma